Borocaptate sodiumBorocaptate sodium
MedChemExpress (MCE)
HY-142041
144885-51-8
BSH
95.0%
-20°C, stored under nitrogen, away from moisture *In solvent : -80°C, 6 months
-20°C, 1 month (stored under nitrogen, away from moisture)
Room temperature in continental US
may vary elsewhere.
Borocaptate sodium is a boron-containing compound that can be used as a therapeutic agent in boron neutron capture therapy (BNCT), exhibiting anticancer activity.
Borocaptate sodium (60 μg 10B/mL, 24 hours) combined with BSO (HY-106376) enhances boron uptake and inhibits cell viability in mouse squamous carcinoma cells, rat glioma cells, and hamster lung cells, with boron uptake increasing as cell viability decreases[3].
Borocaptate sodium (55 mg/kg, i.v., single dose) selectively targets intracranial tumors in dogs and inhibits their growth[2].
| | | |
| | | | | |
[1]. Bendel P, et al. Optimal detection of the neutron capture therapy agent borocaptate sodium (BSH): A comparison between and NMR[J]. Medical Physics, 2001, 28(2): 178-183. [Content Brief]
[2]. Kraft SL, et al. Borocaptate sodium: a potential boron delivery compound for boron neutron capture therapy evaluated in dogs with spontaneous intracranial tumors. Proc Natl Acad Sci U S A. 1992 Dec 15
89(24):11973-7. [Content Brief]
[3]. Yoshida F, et al. Enhancement of sodium borocaptate (BSH) uptake by tumor cells induced by glutathione depletion and its radiobiological effect. Cancer Lett. 2004 Nov 8
215(1):61-7. [Content Brief]
[4]. Kokai-Kun J F, et al. Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model[J]. Journal of antimicrobial chemotherapy, 2007, 60(5): 1051-1059. [Content Brief]